|
Corporate Presentation |
|
AASLD - The Liver Meeting Presentation |
|
A 52-Week Multi-Center Double-Blind Randomized Phase 2 Study of Seladelpar, a Potent and Selective Peroxisome Proliferator-Activated Receptor Delta (PPAR) Agonist, in Patients with Nonalcoholic Steatohepatitis (NASH) |
|
The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice |
|
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study |
